Moreover, the presence of CT26/HER2 tumors was unable to prevent 4T1.2/HER2 cells from inducing tumor regression, suggesting that the CT26/HER2 tumor-derived in vivo environment may not have any influence on the immunogenicity of 4T1.2/HER2 cells. This evidence concerns the gene DDX53 and neoplasm.